Which company does the R&D and production of neratinib/neratinib belong to?

Neratinib/Neratinib is an oral irreversible human epidermal growth factor receptor HER1, HER2 and HER4 inhibitor with significant efficacy. Initially, it was developed by Pfizer, a world-renowned pharmaceutical company. However, with the passage of time and business adjustments, the R&D and production rights of neratinib eventually fell into the hands of Puma Biotechnology, Inc. After Puma Biotechnology took over, it conducted in-depth research and further development of neratinib, which has shown excellent results in the treatment of HER2-positive (HER+) breast cancer.

The unique mechanism of action of neratinib is that it can permanently attach to the receptors of cancer cells, thereby blocking the growth signals of cancer cells, ultimately leading to the death of cancer cells. Neratinib is mainly used to treat adult patients with early-stage HER2-positive breast cancer who have previously received trastuzumab. For these patients, neratinib is used as adjuvant therapy to help reduce the risk of cancer recurrence. In addition, the combination of neratinib and capecitabine has shown promising therapeutic effects in patients with advanced or metastatic HER2+ breast cancer who have tried two or more other HER2 breast cancer treatments.

Although diarrhea is one of the common side effects of neratinib, this adverse reaction can be effectively controlled through reasonable antidiarrheal prevention and adjustment of drug dosage. If a patient is being treated for early stageHER2+ breast cancer, may need up to1 year; if a patient is being treated for advanced or metastaticHER2+ breast cancer, neratinib is taken for 21-day treatment cycles. The number of cycles completed will depend on how the cancer responds to the treatment and whether there are any side effects.